Read by QxMD icon Read

hcv infection dialysis

Marie-Patrice Halle, Simeon-Pierre Choukem, Francois Folefack Kaze, Gloria Ashuntantang, Vanessa Tchamago, Yannick Mboue-Djieka, Elvis Temfack, Henry Namme Luma
INTRODUCTION: Maintenance hemodialysis is a high-risk environment for transmission of blood-borne viruses. We aimed to assess the seroconversion rates of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immune deficiency virus (HIV) infections in patients on maintenance hemodialysis in a tertiary care hospital in Cameroon. MATERIALS AND METHODS: Patients with serology records at initiation of hemodialysis, and a minimum duration on hemodialysis of 4 months were included...
September 2016: Iranian Journal of Kidney Diseases
Patrice Cacoub, Anne Claire Desbois, Corinne Isnard-Bagnis, Dario Rocatello, Clodoveo Ferri
Hepatitis C virus (HCV) infection is associated with tremendous morbidity and mortality due to liver complications. HCV infection is also associated with many extrahepatic manifestations including cardiovascular diseases, glucose metabolism impairment, cryoglobulinemia vasculitis, B cell non-Hodgkin lymphoma and chronic kidney disease (CKD). Many studies have shown a strong association between HCV and CKD, by reporting (i) an increased prevalence of HCV infection in patients on haemodialysis, (ii) an increased incidence of CKD and proteinuria in HCV-infected patients, and (iii) the development of membranoproliferative glomerulonephritis secondary to HCV-induced cryoglobulinemia vasculitis...
October 2016: Journal of Hepatology
Özgür Can, Ali Murat Gökçe, Mustafa Canbakan, Pınar Ata, Gülizar Manga Şahin, Mesut İzzet Titiz, Süheyla Apaydın
BACKGROUND Sensitization is one of the most important barriers against transplantation. Our aim was to evaluate the sensitization status of our patients awaiting cadaveric transplantation and to identify factors causing sensitization. MATERIAL AND METHODS A total of 140 patients on the cadaveric waiting list during January 2014 were included in this retrospective cross-sectional study. The parametric t-test and the non-parametric chi-square test were used to detect differences between PRA-positive and -negative patients...
September 13, 2016: Annals of Transplantation: Quarterly of the Polish Transplantation Society
Ioannis Papayannis, P Patel
Kidney transplantation from hepatitis C virus (HCV)-positive donors to HCV-positive recipients has always been controversial regarding the safety and the outcomes. In the posttransplant period, treatment of hepatitis C with interferon-based regimens could lead to serious side effects. A patient with chronic hepatitis C and nephropathy, on dialysis, underwent renal transplantation from an HCV-positive donor and received direct-acting antiviral (DAA) drugs thereafter. His renal and liver functions, as well as the hepatitis C viral load, were evaluated at predetermined intervals throughout and after his treatment...
September 2016: Progress in Transplantation
Mohammad Reza Hasanjani Roushan, Safa Farokhtabar, Masomeh Bayani, Sepideh Siadati
BACKGROUND: Hemodialysis patients are potentially susceptible to infection with blood-borne viral agents, especially hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). OBJECTIVES: The aim of this study was to evaluate the prevalence and incidence of HBV, HCV, and HIV infections in hemodialysis patients. PATIENTS AND METHODS: This study was carried out in 482 hemodialysis patients who had been referred to eight dialysis centers in the Mazandaran province in Iran from 2012 - 2014...
May 2016: Nephro-urology Monthly
Sammy Saab, Melissa A Jimenez, Sherona N Bau, Gina Choi, Francisco A Durazo, Mohammed M El-Kabany, Steven-Huy B Han, Ronald W Busuttil
BACKGROUND: The use of direct acting agents has changed the management paradigm of hepatitis C (HCV) in liver transplant (LT) recipients. However, the appropriate antiviral regimen in LT recipients on hemodialysis (HD) remains unclear. METHODS: We retrospectively evaluated the safety and efficacy of sofosbuvir-based LT recipients on HD followed at the University of California Los Angeles. RESULTS: Twelve LT recipients on HD were treated for recurrent HCV with sofosbuvir-based therapy...
August 19, 2016: Journal of Clinical Gastroenterology
Jessica I Bravo Zuñiga, César Loza Munárriz, Jesús López-Alcalde
BACKGROUND: The hepatitis C virus (HCV) infection affects about 2% of the world's population and can cause chronic liver infection and persistent long-term sequelae such as cirrhosis and liver cancer.The prevalence of HCV infection among people on haemodialysis is often higher than the general population. The virus is easily transmitted parenterally, and blood transfusions have previously played a significant role in transmission; however, erythropoietin therapy has reduced the need for transfusions, and coupled with improved screening of donated blood, has significantly decreased transmission by transfusion...
2016: Cochrane Database of Systematic Reviews
S K Agarwal, D Bhowmik, S Mahajan, S Bagchi
There is no published study from India on hepatitis C virus (HCV) treatment in dialysis patients. Patients on dialysis with HCV infection treated with pegylated interferon (Peg-INF) monotherapy were studied. All patients were subjected to HCV-polymerase chain reaction, viral load, genotype, and liver biopsy. Quantitative HCV-RNA was performed monthly. Patients with genotype 1 and 4 were given 12 month therapy while those with genotypes 2 and 3 were given 6 months therapy. Response was classified as per standard criteria of rapid virological response (RVR), early virological response (EVR), end of treatment response (ETR), and sustained virological response (SVR)...
July 2016: Indian Journal of Nephrology
Shaimaa A Senosy, Ekram M El Shabrawy
BACKGROUND: The prevalence of HCV infection among hemodialysis patients (HD) varies from country to country and from one center to another. Despite the existence of guidelines for a comprehensive infection control program, Egypt is one of the countries with high HCV prevalence. In Egypt, the prevalence of HCV in haemadalysis patients (2015) was 50.7%. OBJECTIVES: (1) To detect the prevalence of hepatitis C virus (HCV) infection and HCV seroconversion among all hemodialysis patients in Beni-Suef governorate, and (2) To detect factors associated with HCV seroconversion...
June 2016: Journal of the Egyptian Public Health Association
Samar Ahmed, Assem El-Sherif
Hepatitis-C virus (HCV) infection remains highly prevalent among hemodialysis (HD) patients, but there is a notable paucity of information on aspects of bio-incompatibility in those infected patients. This study aimed to answer the following question: In HD patients, does chronic HCV infection attenuate the acute inflammatory response that results from contact of patient's blood with the dialyzer membrane? We elected to investigate the contact response in the initial 15 min of a standardized single dialysis session in a before-after design...
July 2016: Saudi Journal of Kidney Diseases and Transplantation
Corinne Isnard Bagnis, Patrice Cacoub
Renal patients are overexposed to hepatitis C virus (HCV) infection. Hepatitis C virus infection may induce renal disease, i.e., cryoglobulinemic membrano-proliferative glomerulopathy and non-cryoglobulinemic nephropathy. Hepatitis C virus impacts general outcomes in chronic kidney disease, dialysis or transplanted patients. Hepatitis C virus infection is now about to be only part of their medical history thanks to new direct acting antiviral drugs exhibiting as much as over 95% of sustained virological response...
September 2016: Infectious Diseases and Therapy
Y Kawakami, M Imamura, H Ikeda, M Suzuki, K Arataki, M Moriishi, N Mori, K Kokoroishi, Y Katamura, T Ezaki, T Ueno, K Ide, T Masaki, H Ohdan, K Chayama
The aim of this study was to evaluate the pharmacokinetic profile of daclatasvir (DCV) and asunaprevir (ASV) dual therapy in haemodialysis patients infected with hepatitis C virus (HCV). Eighteen haemodialysis patients and 54 patients with normal renal function were treated with DCV and ASV dual therapy for 24 weeks. We evaluated the pharmacokinetic profiles of DCV and ASV and examined the rate of sustained virological response 12 weeks after the end of treatment (SVR12 ) and incidence of adverse events during treatment of haemodialysis patients infected with chronic HCV genotype 1 infection...
June 27, 2016: Journal of Viral Hepatitis
Hussein El-Fishawy, Gamal Saadi, May Hassaballa, Mohamed Hussein, Wahid Doss, Gaafar Ragab, Rashad Barsoum
Egypt, the single country with highest incidence of HCV infection in the world, has embarked on a government-sponsored mass treatment program using several combinations of DAAs. Recognizing the importance of extrahepatic manifestations, independently of the hepatic, a subcommittee was assigned to develop national guidelines for respective prioritizing indications and protocols. It evaluated the benefit of treating patients with different extrahepatic manifestations, and reviewed relevant clinical trials and guidelines concerning DAA combinations available in Egypt...
May 2016: Journal of Advanced Research
Sandra Beinhardt, Ramona Al Zoairy, Peter Ferenci, Karin Kozbial, Clarissa Freissmuth, Rafael Stern, Albert Friedrich Stättermayer, Rudolf Stauber, Michael Strasser, Heinz Zoller, Bruno Watschinger, Alice Schmidt, Michael Trauner, Harald Hofer, Andreas Maieron
DAA-based regimens for chronic hepatitis C infection encourage treatment of "difficult-to-treat" cohorts. This study investigated efficacy and safety of DAA-based regimens in HCV patients on dialysis or postkidney or liver/kidney transplantation. Twenty-five patients treated with DAA combinations were evaluated: 10 were on dialysis (eight: hemodialysis, two: peritoneal dialysis), eight were kidney transplant recipients, and seven were liver/kidney transplant recipients. Except for one patient treated with daclatasvir ([DCV]/60 mg/QD)/simeprevir ([SMV]/150 mg/QD), the others received sofosbuvir-based regimens ([SOF];400 mg/QD) combined with SMV:eight, DCV:13 or either ledipasvir ([LDV]90 mg/QD), ribavirin ([RBV];weight based) or pegylated interferon/RBV...
September 2016: Transplant International: Official Journal of the European Society for Organ Transplantation
Seng Gee Lim
The recent outbreak of hepatitis C virus (HCV) at Singapore General Hospital (SGH) has highlighted the dangers of viral hepatitis. In this case, infection control and environmental contamination were the culprits, particularly, a drop of blood containing 5 million IU HCV. From a broader perspective, there has been a revolution in HCV therapy with the recent rapid evolution of short-term (12 weeks) safe, all oral directly- acting antiviral (DAA) therapy leading to cure rates of 90% to 100%, even in previously difficult to treat patients with liver cirrhosis, previous treatment failure and those on immunosuppression...
January 2016: Annals of the Academy of Medicine, Singapore
(no author information available yet)
No abstract text is available yet for this article.
May 2016: American Journal of Transplantation
Ryoichi Miyazaki, Kyoko Miyagi
The prevalence of anti-hepatitis C virus (HCV)antibodies is higher in hemodialysis patients than in the general population, and several studies have reported poor vital prognosis in HCV-infected dialysis patients because infection with HCV is not only the cause of cirrhosis and hepatocellular carcinoma, but also a risk factor for cardiovascular disease. Although sustained virologic response (SVR) is achievable with interferon and ribavirin in dialysis patients, SVR rates are lower, and the use of ribavirin is challenging because of the risk of hemolytic anemia...
October 2016: Therapeutic Apheresis and Dialysis
Elise J Smolders, Clara T M M de Kanter, Bart van Hoek, Joop E Arends, Joost P H Drenth, David M Burger
Hepatitis C virus (HCV)-infected patients often suffer from liver cirrhosis, which can be complicated by renal impairment. Therefore, in this review we describe the treatment possibilities in HCV patients with hepatic and renal impairment. Cirrhosis alters the structure of the liver, which affects drug-metabolizing enzymes and drug transporters. These modifications influence the plasma concentration of substrates of drugs metabolized/transported by these enzymes. The direct-acting antivirals (DAAs) are substrates of, for example, cytochrome P450 enzymes in the liver...
July 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
Marco Ladino, Fernando Pedraza, David Roth
Soon after the hepatitis C virus (HCV) was identified in 1989, it was recognized that the prevalence of infection in patients with ESRD far exceeded that in the general population. Infection with HCV predisposes to the hepatic complications of cirrhosis and hepatocellular carcinoma. However, important extrahepatic manifestations include immune complex glomerular disease, accelerated progression of CKD, increases in cardiovascular event risk, and lymphoproliferative disorders. Advances in understanding the molecular biology of HCV have ushered in a new era in the treatment of this infection...
August 2016: Journal of the American Society of Nephrology: JASN
Fabrizio Fabrizi, Paul Martin, Piergiorgio Messa
The evidence that chronic hepatitis C plays a detrimental role in survival among patients on maintenance dialysis or renal transplant recipients promotes the antiviral treatment of hepatitis C virus (HCV) among chronic kidney disease patients. Also, it seems that HCV infection is associated with an increased risk of developing chronic kidney disease in the adult general population. Interferon-based regimens have provided limited efficacy and safety among chronic kidney disease patients, whereas the advent of the new direct-acting antivirals for the treatment of hepatitis C (launched over the past 5 years) has given the opportunity to reach sustained virologic response rates of 90% for many patient groups...
May 2016: Kidney International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"